Trial Profile
An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2012
Price :
$35
*
At a glance
- Drugs Amlodipine/losartan (Primary) ; Amlodipine; Losartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 01 Feb 2012 Results published in the American Journal of Cardiovascular Drugs.
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
- 25 Jul 2009 New trial record